Australia's most trusted
source of pharma news
Friday, 20 February 2026
Posted 11 August 2025 AM
Within hours of taking on the top job at Novo Nordisk, new CEO Mike Doustdar has come out fighting, frankly addressing the company's challenges and laying out his plans to "play to win".
The company's sixth CEO, Doustdar takes the helm at a critical time, with Novo's performance coming under increasing scrutiny from investors as share prices fall in the face of stiff competition.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.